Pembrolizumab plus concurrent chemoradiotherapy shows ongoing antitumor activity after about 5 years of follow-up in patients ...

The National Comprehensive Cancer Network® (NCCN®) and the NCCN Foundation® proudly announce four recipients for the 2025 NCCN Foundation Young Investigator Awards (YIA). These awards provide ...

Yelena Y. Janjigian, MD, discusses the long-term survival data from the KEYNOTE-811 trial of pembrolizumab plus trastuzumab ...

MSD’s monoclonal antibody, indicated for 15 types of cancer, smashed industry records with sales of $27.3 billion in 2024, ...